|Information for Students|
|Information for SMEs|
|Information for the Community|
|Tricolour Venture Fund|
|Dare to Dream Internship|
|Business Plan Competitions|
|The QCBV Team|
|Kinnear Business Plan Competition|
TriColour Venture Fund
The Tricolour Venture Fund is Canada's first student-advised venture capital fund. This VC fund allows students from the Bachelor of Commerce and Full-Time MBA programs to gain hands-on experience in managing a multi-million dollar fund. Students meet directly with potential portfolio companies, assessing the opportunities, conducting due diligence and making recommendations to the Investment Advisory Board: a committee of seasoned entrepreneurs, angel investors, and venture capitalists. All deals are syndicated in cooperation with some of Canada's leading venture capital companies and angel investors.
The Fund is seeded with contributions from alumni and friends of Queen's University, and all proceeds from the Fund are reinvested into maintaining and expanding the innovative educational programme.
The TriColour Venture Fund course runs annually from January through April. Executive summaries are collected throughout the year until the second week of January.
The students perform an initial screening of the list of submissions using a framework designed to evaluate each submission as an investment opportunity. For each submission, the students investigate the idea or technologies involved, the management team behind each submission, the applicable market, the competition, and impact of an investment by the fund. The students will select 2 to 3 companies for deeper analysis by the second week of February.
From mid-February throughout March, the students conduct due-diligence on their short-listed companies. This evaluation process will involve face-to-face meetings, pitch presentations, and financial modeling and analysis.
In the first week of April, the students make investment recommendations to the Investment Advisory Board for the 2 to 3 companies that they analyzed. Any company recommended for investment will be eligible to receive up to $150,000 in funding as a co-investment with the company’s existing investor or potential new investors.
The Investment Advisory Board then acts on the recommendations of the students and engages the eligible companies in concluding due-diligence work and negotiating investment terms.
Fund submissions are to meet the following criteria:
- Companies should already be funded through friends and family, IRAP, OCE, IAF, or any angel or venture capital investor
- We are looking for early stage companies that are seeking funding for growth
- The ideal companies would be seeking an investment round amount of up to $1M
- Submitting companies must have already engaged a lead investor
The Fund actively encourages entrepreneurs to submit Executive Summaries or PowerPoint presentations for the Fund's consideration. The description of your early-stage venture should include an introduction to your team, an overview of the opportunity, and a clear articulation of the competitive advantages fuelling your new venture.
Contact us to participate in the fund.
Our investment portfolio currently includes the following companies:
- Datec Coating Corporation
Datec Coating Corporation is an innovative high tech materials science company that provides coatings and coating services for high performance coatings development, coating applications and heating solutions.
SPARQ Systems Inc.
SPARQ Systems is an Ontario-based manufacturer of smart micro-inverters for photovoltaic (PV) power systems. A micro-inverter is a miniaturized voltage converter suitable for use with solar panels, significantly improving the overall efficiency of PV systems under normal as well as adverse conditions.
Vennsa Technologies, Inc.
Vennsa Technologies is the leading supplier of automated debugging and error localization software. Leveraging over 15 years of cutting edge research and patented IP, Vennsa's technology has been validated by numerous industrial partners. Its product automates the manual tasks of debug and error localization at the register transfer level (RTL), drastically reducing the time required to locate and correct errors.
Profound Medical Inc.
Arguably the best medical imaging tool in common use today, Magnetic Resonance Imaging (MRI) enables a clinician to “see” in detail the internal organs of a patient non-invasively. Ultrasound imaging and thermal coagulation therapy have proven utility in several medical applications. When combining the two methodologies, the opportunity exists for an optimal and vastly superior clinical outcome. PMI has developed a novel MRI-compatible ultrasound energy wand to deliver controlled thermal therapy to the regions of the prostate gland via a trans-urethral approach. The system has been extensively tested and delivered consistent and predictable proof-of-concept results in mathematical, gel, pre-clinical models.
CrowdWave® engages fans interactively. Fans connect through play with each other, with the team and with sponsors. Our proprietary system of cameras, server and software captures and interprets fan movement to control branded big-screen experiences. Fans cooperate or compete, section versus section, level versus level, simply by moving their arms. Those movements control games and polls customized for teams and sponsors during breaks in the on-court, on-field or on-ice action. CrowdWave® entertains, CrowdWave® connects, CrowdWave® drives premium sponsorship revenue.
Therapeutic Monitoring Systems
Therapeutic Monitoring Systems Inc. (TMS) is developing clinical decision support software applications that provide critical care physicians and staff with remarkable insights into patient status and prognosis. Seamlessly integrating with existing monitors, our CIMVA family of software applications continuously analyze patient vital sign variability in order to detect changes in patient health status not otherwise observable using current standard-of-care monitoring in the ICU. Clinical studies to date strongly indicate that CIMVA holds the promise of significantly improving the diagnosis, prognosis and treatment of critically ill patients, enabling more timely and effective critical care decisions.